0.415
0.01 (2.47%)
前收盘价格 | 0.405 |
收盘价格 | 0.418 |
成交量 | 29,027 |
平均成交量 (3个月) | 379,092 |
市值 | 7,461,986 |
价格/销量 (P/S) | 0.560 |
股市价格/股市净资产 (P/B) | 0.560 |
52周波幅 |
营业毛利率 | -24.01% |
营业利益率 (TTM) | 13.12% |
稀释每股收益 (EPS TTM) | -0.060 |
季度收入增长率 (YOY) | -23.10% |
总债务/股东权益 (D/E MRQ) | 4.73% |
流动比率 (MRQ) | 5.61 |
营业现金流 (OCF TTM) | -1.87 M |
资产报酬率 (ROA TTM) | -10.11% |
股东权益报酬率 (ROE TTM) | -28.44% |
市场趋势
短期 | 中期 | ||
行业 | Specialty Chemicals (US) | 看涨 | 混合的 |
Specialty Chemicals (全球的) | 看涨 | 混合的 | |
股票 | BioNexus Gene Lab Corp | - | - |
AIStockmoo 评分
分析师共识 | 2.0 |
内部交易活动 | NA |
价格波动 | -2.0 |
技术平均移动指标 | 0.0 |
技术振荡指标 | -0.5 |
平均 | -0.13 |
BioNexus Gene Lab Corp through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of 11 different diseases. |
|
部门 | Basic Materials |
行业 | Specialty Chemicals |
投资方式 | Small Value |
内部持股比例 | 43.72% |
机构持股比例 | 0.88% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。
投资组合